Sovereign Nations. Different Laws. One Complicated Payments System.
Sovereign Nations. Different Laws. One Complicated Payments System. On Indigenous Peoples' Day, it's time to examine why tribal gaming, ...
The Consumer Product Safety Commission announced a recall of approximately 2,300 units of Benadryl liquid elixir sold on Amazon from July 2023 to August 2024 due to packaging that fails to meet federal child safety requirements. The bottles, manufactured by Arsell and sold between $16 and $19, were not packaged in child-resistant containers as mandated by the Poison Prevention Packaging Act for medications containing diphenhydramine.
Kenvue, the manufacturer of Benadryl, clarified that the recalled product was never authorized for sale in the United States. "The recalled lot of Benadryl Liquid Elixir is not authorized for sale in the United States," a company spokesperson stated. "The bottles were manufactured in Canada for Canadian consumers and were designed to meet Canada's packaging regulations."
The company believes the product was diverted from Canada and inappropriately sold in the United States by an unauthorized third-party online seller operating through Amazon's marketplace. This product diversion highlights vulnerabilities in e-commerce platforms that allow international products to reach U.S. consumers without proper regulatory compliance verification.
The Poison Prevention Packaging Act specifically requires child-resistant packaging for medications containing diphenhydramine, the active ingredient in Benadryl, due to the serious risk of poisoning if young children access and ingest the medication. Diphenhydramine overdoses in children can cause severe symptoms, including seizures, hallucinations, cardiac arrhythmias, and, in extreme cases, death.
The recalled product is identifiable by its pink-and-white paper box with "Benadryl" in blue text. A white label on the bottom of the package contains the code "X003VRIGUL" written in black text. Consumers who purchased this product should immediately secure it away from children and initiate a refund.
The CPSC instructs consumers to contact Arsell for a full refund by emailing recall@arsellsupport.com with their Amazon order number and a photo demonstrating disposal of the recalled Benadryl. Although only the bottle packaging is technically recalled, not the medicine itself, both should be disposed of to ensure complete removal from households where children may be present.
Kenvue emphasized its commitment to product safety in its statement: "We take the quality, packaging, and safety of our products very seriously, and always recommend medication be kept out of the reach of children. We are investigating this matter."
The Benadryl recall exposes systematic compliance gaps in third-party marketplace sales on platforms like Amazon, where sellers can list products without adequate verification of regulatory compliance for destination markets. Products manufactured for one country's regulatory framework can reach consumers in jurisdictions with different requirements, creating safety risks that neither manufacturers nor regulators anticipated.
Canadian packaging regulations differ from U.S. requirements under the PPPA, allowing products that meet Canadian standards but fail U.S. compliance. When unauthorized sellers divert these products to American consumers through e-commerce channels, the regulatory protections designed to prevent child poisoning are circumvented entirely.
Despite the unauthorized nature of the diversion, Kenvue faces reputational risk from products bearing its Benadryl brand being sold in non-compliant packaging. The incident demonstrates that manufacturers must monitor not only authorized distribution channels but also gray-market activities that can undermine brand integrity and consumer safety.
The 13-month sales period before recall detection—from July 2023 to August 2024—suggests inadequate monitoring systems for identifying unauthorized product diversions and regulatory non-compliance in third-party marketplace sales. Both manufacturers and e-commerce platforms need enhanced surveillance capabilities to detect and prevent such incidents before products reach consumers.
The Benadryl recall follows similar actions affecting iHerb's California Gold Nutrition iron supplements and represents a broader pattern of child-resistant packaging failures across the supplement and over-the-counter medication sectors. These incidents reveal systemic quality-control weaknesses, where even well-established brands and major retailers struggle to maintain consistent compliance with decades-old child-safety regulations.
For businesses operating in regulated product categories, the Benadryl case underscores the importance of monitoring all sales channels—including unauthorized third-party sellers—that could expose consumers to non-compliant products bearing the company's brand. Quality management systems must extend beyond manufacturing and authorized distribution to encompass marketplace surveillance and rapid-response capabilities to address unauthorized sales.
Subscribe to Our Newsletter
Stay informed with daily insights on compliance, regulation, and industry trends affecting highly regulated industries.
Subscribe Here
Read Our Blog
Explore in-depth analysis and expert perspectives on navigating the complex regulatory landscape for hemp, CBD, and botanical products.
Visit Our Blog
Reach Out to Learn More About Our Products
Discover how Q-Trust can strengthen your compliance framework, adapt to rapid regulatory changes, and protect your business from federal and state enforcement actions.
Contact Us
